Applications of spermine or its pharmaceutically acceptable derivative in preparation of an SAICAR synthetase activity interfering agent or inhibitor. Applications of spermine or its pharmaceutically acceptable derivative in preparation of antitumor drug.

A Krill oil preparation including a reduced amount of trimethylamine of 5 mgN/100 g or less, or more than 700 ppm by weight of endogenous calcium and/or less than 1200 ppm by weight of sodium. A process of making such a Krill oil preparation that includes a step of extracting Krill oil from Krill with a solvent mixture of one or more polar solvents and one or more non-polar solvents. A method of treating a human in need of treatment that includes administering to the human an amount of such a Krill oil preparation.

The present disclosure provides use of a norepinephrine or a β-adrenergic receptor inhibitor in the preparation of a medicament for nerve injury repair in diabetes, and belongs to the technical field of nerve repair drugs. By inhibiting norepinephrine secretion or antagonizing β2-adrenergic receptors, the present disclosure promotes the expression of neurotrophic factors in epithelial cells to further regulate nerve repair. Therefore, the present disclosure provides the use of a norepinephrine inhibitor or a β-adrenergic receptor inhibitor in the preparation of a medicament for nerve injury repair in diabetes. The inhibitor provided by the present disclosure features excellent stability and low cost, and has excellent clinical application prospects.

The present disclosure provides use of a norepinephrine or a β-adrenergic receptor inhibitor in the preparation of a medicament for nerve injury repair in diabetes, and belongs to the technical field of nerve repair drugs. By inhibiting norepinephrine secretion or antagonizing β2-adrenergic receptors, the present disclosure promotes the expression of neurotrophic factors in epithelial cells to further regulate nerve repair. Therefore, the present disclosure provides the use of a norepinephrine inhibitor or a β-adrenergic receptor inhibitor in the preparation of a medicament for nerve injury repair in diabetes. The inhibitor provided by the present disclosure features excellent stability and low cost, and has excellent clinical application prospects.

Disclosed aspects include characterizing of the metabolite secretome of apoptotic cells, deciphering metabolite-based communication between dying cells and neighboring live cells, and harnessing components of the secretome for beneficial effects in vivo. In representative embodiments, a composition comprising, consisting essentially of, or consisting of an effective amount of a plurality of metabolite compounds derived from an apoptotic cell is disclosed, as are methods of treating an inflammatory condition in a subject and modulating gene expression in a subject using the composition.

Disclosed aspects include characterizing of the metabolite secretome of apoptotic cells, deciphering metabolite-based communication between dying cells and neighboring live cells, and harnessing components of the secretome for beneficial effects in vivo. In representative embodiments, a composition comprising, consisting essentially of, or consisting of an effective amount of a plurality of metabolite compounds derived from an apoptotic cell is disclosed, as are methods of treating an inflammatory condition in a subject and modulating gene expression in a subject using the composition.

Disclosed aspects include characterizing of the metabolite secretome of apoptotic cells, deciphering metabolite-based communication between dying cells and neighboring live cells, and harnessing components of the secretome for beneficial effects in vivo. In representative embodiments, a composition comprising, consisting essentially of, or consisting of an effective amount of a plurality of metabolite compounds derived from an apoptotic cell is disclosed, as are methods of treating an inflammatory condition in a subject and modulating gene expression in a subject using the composition.

Highly bioavailable compositions and related methods of improving the bioavailability of one or more compounds are disclosed. The compositions and methods disclosed herein may be employed to improve the bioavailability of poorly soluble or poorly bioavailable ingredients (e.g., curcumin) in a subject (e.g., a mammal).

Highly bioavailable compositions and related methods of improving the bioavailability of one or more compounds are disclosed. The compositions and methods disclosed herein may be employed to improve the bioavailability of poorly soluble or poorly bioavailable ingredients (e.g., curcumin) in a subject (e.g., a mammal).

A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD.sup.+, or a substance involved in the metabolism of any of these substances.